

Application No. 10/715,667  
Resp to OA filed June 21, 2006  
Office Action dated April 28, 2006

REMARKS

Status of the Claims

Claims 13-28 stand rejected. Claims 13-16 and 18-21 are amended herein. Claim 17 is canceled herein without prejudice. Claims 13-16 and 18-28 are currently pending. For the Examiner's convenience, a "clean" copy of the currently pending claims is provided as Appendix A. Applicant reserves the right to pursue the subject matter of the claims prior to the amendments in one or more subsequently filed applications. Support for the amendments can be found throughout the specification, e.g., at least at page 13, line 28, to page 15, line 11.

Outstanding Rejections

The Office Action asserts that claims 13-28 fail to meet the enablement and written description standards of 35 U.S.C. § 112, first paragraph. Applicant respectfully disagrees. Nonetheless, in order to expedite prosecution, Applicant has amended the claims herein, rendering the rejections moot.

Claim 13 (and dependent claims 14-16, 18-20, and 25-28) as amended, is directed to an isolated polypeptide having HPR2 polypeptide activity comprising amino acids 24-318 of SEQ ID NO:21. Similarly, claim 21 (and dependent claims 22-24), as amended, is directed to a polypeptide expressed by a process comprising providing an expression vector comprising a nucleotide sequence encoding an HPR2 polypeptide comprising amino acids 24-318 of SEQ ID NO:21. The specification describes how to make and use several embodiments of the pending claims, including but not limited to HPR2, HPR2-ex9, and HPR2-ex8-ex9. Thus, the pending claims satisfy the enablement and written description standards of 35 U.S.C. § 112, first paragraph.

For the foregoing reasons, Applicant believes claims 13-16 and 18-28 are in condition of allowance. Should the Examiner wish to discuss any further matter, she is invited to contact the undersigned at the number listed below.

Respectfully submitted,



Thomas J. Wrona, Ph.D.  
Attorney for Applicants  
Registration No. 44,410  
Telephone (206) 265-7374

Immunex Corporation  
Law Department  
1201 Amgen Court West  
Seattle, WA 98119

**CERTIFICATE OF FACSIMILE TRANSMISSION**

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on the date indicated below.

Signed:   
Nanci M. Kersten

Date: June 21, 2006

Application No. 10/715,667  
Resp to OA filed June 21, 2006  
Office Action dated April 28, 2006

Appendix A

13. An isolated polypeptide having HPR2 polypeptide activity comprising amino acids 24-318 of SEQ ID NO:21.
14. The polypeptide of claim 13 wherein the polypeptide comprises amino acids 24 through 629 of SEQ ID NO:21.
15. The polypeptide of claim 14 wherein the polypeptide comprises amino acids 1 through 629 of SEQ ID NO:21.
16. The polypeptide of claim 13 wherein the polypeptide comprises amino acids 24 through 348 of SEQ ID NO:21 and amino acids 349 through 356 of SEQ ID NO:25.
18. The polypeptide of claim 16 comprising amino acids 1 through 348 of SEQ ID NO:21.
19. The polypeptide of claim 13 wherein the polypeptide further comprises amino acids 319 through 565 of SEQ ID NO:23.
20. The polypeptide of claim 19 wherein the polypeptide comprises the amino acid sequence of SEQ ID NO:23.
21. A polypeptide expressed by a process comprising providing an expression vector comprising a nucleotide sequence encoding an HPR2 polypeptide comprising amino acids 24-318 of SEQ ID NO:21.
22. The polypeptide of claim 21, wherein the polypeptide is produced by a method further comprising purifying the polypeptide.
23. The polypeptide of claim 21 in non-glycosylated form.
24. The polypeptide of claim 21, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell selected from the group consisting of mammalian cells, prokaryotic cells, and yeast cells.
25. The polypeptide of claim 13, wherein the polypeptide is produced by a process comprising culturing a recombinant host cell under conditions promoting expression of said polypeptide.

Application No. 10/715,667  
Resp to OA filed June 21, 2006  
Office Action dated April 28, 2006

26. The polypeptide of claim 25 in non-glycosylated form.
27. The polypeptide of claim 25, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell comprising an expression vector comprising a nucleic acid encoding said polypeptide.
28. The polypeptide of claim 25, wherein the polypeptide is produced by a method comprising culturing a recombinant host cell selected from the group consisting of mammalian cells, prokaryotic cells, and yeast cells.

hf081001 6/21/06